Metachromatic Leukodystrophy (MLD)

Metachromatic leukodystrophy (MLD) is the most common leukodystrophy, caused by deficiency of arylsulfatase A (ARSA) and progressive accumulation of sulfatide in the nervous system, leading to severe demyelination — now treatable by gene therapy (atidarsagene autotemcel) in pre-symptomatic and early-symptomatic patients.

Table of Contents

  1. Overview and Biochemistry
  2. Clinical Forms
  3. Diagnosis
  4. Gene Therapy — Atidarsagene Autotemcel (Libmeldy)
  5. Hematopoietic Stem Cell Transplantation (HSCT)
  6. Symptomatic Management and Supportive Care
  7. Newborn Screening and Future Directions
  8. Key Research Papers
  9. Connections
  10. Featured Videos

Overview and Biochemistry

Metachromatic leukodystrophy (MLD) takes its name from an unusual staining property: accumulated sulfatide in nerve tissue turns yellow-brown rather than the expected purple when exposed to cresyl violet dye — a shift called metachromasia. This seemingly arcane laboratory finding points to a devastating molecular defect that destroys the myelin sheaths coating nerves throughout the brain, spinal cord, and peripheral nervous system.

The root cause is deficiency of the lysosomal enzyme arylsulfatase A (ARSA), also called cerebroside-3-sulfate 3-sulfohydrolase. Normally, ARSA cleaves a sulfate group from 3-O-sulfogalactosylceramide — commonly known as sulfatide — the most abundant non-glycosylated sulfoglycolipid in myelin. Without functional ARSA, sulfatide cannot be degraded and accumulates progressively inside the lysosomes of oligodendrocytes (the myelin-making cells of the central nervous system), Schwann cells (peripheral myelin), and neurons. This lysosomal storage drives cell death and progressive demyelination.

The ARSA gene sits on chromosome 22q13.33 and is inherited in an autosomal recessive pattern — meaning a child must inherit a defective copy from each parent to develop MLD. Carriers (with one functional copy) are unaffected. The two most clinically important ARSA mutations are:

A second molecular player is saposin B (SAP-B), a small non-enzymatic activator protein encoded by the PSAP gene. SAP-B is required to present sulfatide to ARSA in the lysosome; without it, ARSA enzyme is present but cannot access its substrate. SAP-B deficiency is a rarer cause of a clinically identical MLD phenotype and must be considered when ARSA enzyme activity appears normal in a patient with typical MLD symptoms.

An important diagnostic pitfall is ARSA pseudodeficiency — a common benign polymorphism (affecting approximately 1% of the population) that reduces ARSA activity to low levels on artificial substrates used in standard enzyme assays. Pseudodeficiency carriers have reduced enzyme activity in the lab but cannot develop MLD and have no clinical disease. Distinguishing true MLD from pseudodeficiency requires DNA mutation analysis and measurement of urinary or CSF sulfatide biomarkers, which are dramatically elevated only in true MLD.

MLD has an estimated prevalence of 1 in 40,000 to 1 in 160,000 live births, making it the most common leukodystrophy. Approximately 1,900 patients are estimated to live in Europe. All racial and ethnic groups are affected, with some founder effects in certain populations (e.g., Navajo Nation, Habbanite Jews).

Back to Table of Contents

Clinical Forms

MLD presents in three age-of-onset subtypes that correlate roughly with the degree of residual ARSA activity. Two null alleles produce the most severe and earliest form; one or more alleles with residual activity yield later, slower disease. The boundaries are not absolute, and some genotype-phenotype correlation exists but is imperfect.

Late Infantile MLD (50–60% of cases)

Onset typically occurs between 12 and 24 months, shortly after normal motor development has begun. The first signs are usually gait disturbance — a child who was walking begins to stumble, fall, or walk on toes. Peripheral neuropathy is prominent early in this form: nerve conduction studies show severely slowed velocities even at initial presentation, reflecting sulfatide accumulation in Schwann cells of peripheral nerves. Hypotonia and loss of deep tendon reflexes accompany this finding.

Over months, the child regresses through motor milestones — losing the ability to walk, then to sit independently. Speech deteriorates. Intellectual function declines. Seizures, optic atrophy (leading to blindness), and eventually decerebrate posturing occur in advanced disease. Without intervention, most children die within 2 to 5 years of symptom onset. This form is driven primarily by null mutations such as IVS2+1G>A.

Juvenile MLD (20–30% of cases)

Onset falls between 4 and 12 years of age. Crucially, the first symptoms in juvenile MLD are often behavioral and cognitive rather than motor — a child previously doing well in school begins to struggle academically, becomes irritable, develops mood swings, or shows personality changes. This cognitive-first presentation frequently delays diagnosis, as behavioral problems in school-age children have a broad differential. Psychiatric features including mood disturbance, anxiety, and occasionally hallucinations may appear.

Motor deterioration follows: ataxia, spasticity, and evidence of peripheral neuropathy emerge. Seizures develop in many patients. The course is slower than late infantile, with survival typically 10 to 20 years after symptom onset, though with progressive disability.

Adult MLD (15–20% of cases)

Onset occurs after age 16, sometimes not until the fourth or fifth decade of life. The psychiatric presentation is the dominant early feature — personality change, depression, psychosis, paranoia, or frank schizophrenia-like illness. Because adult-onset MLD is rare and the psychiatric symptoms are indistinguishable clinically from primary psychiatric disorders, patients are frequently misdiagnosed and treated with antipsychotics and mood stabilizers for years before the correct diagnosis is reached.

Over time, cognitive decline becomes apparent — memory impairment, executive dysfunction, dementia. Motor features emerge later: ataxia, spasticity, peripheral neuropathy. Brain MRI showing characteristic white matter changes is often the first clue that redirects evaluation toward a metabolic or genetic cause. Survival is highly variable; some patients live for decades after onset with slowly progressive disability.

Back to Table of Contents

Diagnosis

Diagnosing MLD requires integrating enzyme biochemistry, biomarkers, genetics, neurophysiology, and neuroimaging. No single test alone is sufficient — the pseudodeficiency pitfall makes this mandatory.

Arylsulfatase A Enzyme Activity

The initial test is measurement of ARSA enzyme activity in peripheral blood leukocytes. In true MLD, activity is markedly reduced to less than 10% of normal. However, pseudodeficiency can produce values in the 5–20% range on the artificial substrate used in standard assays. A low ARSA value alone is not sufficient to confirm MLD — it must always be paired with sulfatide biomarker measurement and/or genetic testing.

Urinary Sulfatide — The Gold-Standard Biomarker

Urinary sulfatide, measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), is dramatically elevated in MLD and is the single most reliable confirmatory biomarker. Critically, urinary sulfatide is not elevated in pseudodeficiency, making it the key discriminating test. Sulfatide can also be measured in cerebrospinal fluid, where elevation confirms CNS involvement.

ARSA Gene Sequencing

Molecular genetic testing identifies pathogenic variants in the ARSA gene and confirms the diagnosis. Sequencing also identifies carrier status in family members. When ARSA activity and sulfatide are discordant, or when ARSA activity is normal in a patient with strong clinical suspicion, PSAP gene testing for SAP-B deficiency should be pursued.

Nerve Conduction Studies

Electrophysiology revealing severe demyelinating peripheral neuropathy — markedly slowed conduction velocities and reduced amplitudes — is an important diagnostic clue, particularly in late infantile MLD where peripheral nerve involvement precedes or accompanies early CNS symptoms. Finding a demyelinating neuropathy in a toddler with regression should immediately prompt MLD evaluation.

Brain MRI

MRI is characteristic in established disease. T2-weighted and FLAIR sequences show confluent hyperintensity in periventricular and deep white matter, typically beginning anteriorly and spreading posteriorly over time. The hallmark pattern — sometimes called "tigroid" or "leopard skin" — reflects perivascular sparing of myelin-rich zones within the area of demyelination, creating a striped or spotted appearance on FLAIR. The corpus callosum and cerebellar white matter are commonly affected. Unlike inflammatory demyelinating diseases, there is no gadolinium enhancement, reflecting the absence of active inflammation. Early in adult-onset MLD, MRI changes may be subtle or confined to frontal white matter.

Newborn Screening

NBS programs for MLD are being piloted in several countries, motivated by the availability of gene therapy that is effective only before or at the earliest stages of disease. The main NBS strategy measures ARSA enzyme activity on dried blood spots, but the pseudodeficiency problem complicates interpretation. Reflex testing with sulfatide biomarkers on the same DBS is being validated as a two-tier approach. No US nationwide mandate for MLD NBS exists as of 2026, though advocacy efforts are active.

Back to Table of Contents

Gene Therapy — Atidarsagene Autotemcel (Libmeldy)

The development of gene therapy for MLD represents one of the most significant milestones in rare disease medicine — transforming a uniformly fatal childhood illness into a potentially manageable condition when caught early enough.

Mechanism

Atidarsagene autotemcel (brand name Libmeldy) is an autologous ex vivo lentiviral gene therapy. The process works as follows:

  1. Hematopoietic stem and progenitor cells (HSPCs) are harvested from the patient's own bone marrow or peripheral blood (mobilized with G-CSF).
  2. In the laboratory, the cells are transduced with a lentiviral vector carrying a functional copy of the human ARSA gene under control of a myeloid-specific promoter.
  3. The patient undergoes myeloablative conditioning (busulfan plus fludarabine) to eliminate the existing defective bone marrow.
  4. The gene-corrected HSPCs are infused back into the patient, where they engraft and reconstitute the hematopoietic system.
  5. Over months to years, gene-corrected cells differentiate into monocytes and macrophages that cross the blood-brain barrier to become microglia — providing supraphysiological levels of ARSA directly within the CNS, far exceeding what allogeneic HSCT can deliver.

The supraphysiological ARSA expression achieved by the transduced cells — many-fold above normal — is believed to account for gene therapy's superior efficacy compared to allogeneic HSCT, where donor cell expression is constrained by normal physiological regulation.

Regulatory Approvals

Libmeldy received European Medicines Agency (EMA) approval in November 2020, becoming the first marketed gene therapy for MLD and one of the first approved for any lysosomal storage disorder affecting the brain. The US FDA granted Breakthrough Therapy designation; a Biologics License Application (BLA) was filed, and FDA approval was granted in August 2024, making it available in the United States.

Approved Indication

The therapy is approved for:

The therapy is not approved for — and is not effective in — symptomatic late infantile MLD, where neurological damage is already severe. This is the fundamental reason that newborn screening is so urgently needed: the treatment window is narrow.

Clinical Evidence

The landmark proof-of-concept study by Biffi et al. (Science, 2013; PMID 23845948) demonstrated that gene-corrected HSCs engrafted, produced supraphysiological ARSA in brain tissue, and prevented or halted neurological disease in treated patients. Follow-up Phase I/II data published in Lancet (Sessa et al., 2016; PMID 27289174; Fumagalli et al., 2022; PMID 35065008) showed that pre-symptomatic late infantile patients treated with gene therapy reached age 4–5 with near-normal neurological development, while untreated siblings used as natural history controls had died or were severely disabled by the same ages. Early symptomatic juvenile patients showed stabilization of disease. These outcomes — dramatic when set against the natural history — formed the basis for regulatory approval.

Practical Limitations

Despite its transformative efficacy, gene therapy for MLD faces significant practical barriers:

Back to Table of Contents

Hematopoietic Stem Cell Transplantation (HSCT)

Before gene therapy, allogeneic hematopoietic stem cell transplantation (HSCT) — bone marrow transplant from a healthy donor — was the only treatment with any disease-modifying potential for MLD. It remains relevant in situations where gene therapy is unavailable, where a closely matched sibling donor exists, or for patients outside gene therapy eligibility criteria.

Mechanism

Like gene therapy, allogeneic HSCT works by introducing ARSA-producing cells into the patient. Donor-derived monocytes and macrophages migrate into the CNS and differentiate into microglia, providing ARSA enzyme to the sulfatide-laden environment. The mechanism is the same; the limitation is that donor cells express ARSA at normal physiological levels — not the supraphysiological levels achieved by gene-corrected autologous cells — which appears to be a critical factor in efficacy.

Efficacy and Limitations

Allogeneic HSCT is effective only when performed in pre-symptomatic or very early symptomatic patients. In the late infantile form, results have been generally disappointing — even when performed before symptoms, many treated children still develop significant neurological disease, though with some slowing of progression. In early juvenile MLD performed pre-symptomatically, HSCT can slow or stabilize disease in a meaningful proportion of patients, but outcomes are inferior to those now demonstrated for gene therapy.

Additional risks of allogeneic HSCT include graft-versus-host disease (GvHD), graft failure, infections during immunosuppression, and the challenges of finding a suitably matched unrelated donor. In comparison, gene therapy using the patient's own cells carries no GvHD risk and no dependency on donor availability.

Current Role

With gene therapy now approved in Europe and the US, allogeneic HSCT for MLD has become a second-line option. It continues to be used where gene therapy is geographically unavailable, where manufacturing delays are prohibitive, or in specific situations such as an available HLA-matched sibling donor. Some centers also use allogeneic HSCT for early adult-onset MLD in patients with preserved function, where limited evidence suggests stabilization is possible in a subset.

Back to Table of Contents

Symptomatic Management and Supportive Care

For patients who are beyond the window for gene therapy or HSCT — including the majority of currently symptomatic late infantile patients and many symptomatic adults — management focuses on controlling symptoms, maintaining function and comfort, and supporting families through a relentlessly progressive illness.

Seizure Control

Seizures occur in a significant proportion of MLD patients as disease advances. Standard anti-epileptic agents are used: levetiracetam and valproate are commonly employed first-line. Seizure control may be challenging in advanced disease, and polytherapy is often required. Carbamazepine and other sodium channel blockers may be used. Benzodiazepines are reserved for acute seizure clusters.

Spasticity and Movement

Progressive spasticity — from upper motor neuron involvement as CNS demyelination advances — causes significant discomfort and functional limitation. Baclofen (oral or intrathecal via implanted pump for severe cases) is the mainstay of spasticity management. Tizanidine is an alternative. Botulinum toxin injections into specific muscles can help focal spasticity. Physiotherapy is essential throughout the disease course to maintain range of motion, prevent contractures, and preserve function as long as possible.

Pain Management

Peripheral neuropathy causes neuropathic pain that can be severe. Gabapentin and pregabalin are first-line agents for neuropathic pain. Low-dose amitriptyline provides additional benefit in some patients and may also help with sleep disturbance. Opioids may be required in advanced disease.

Nutrition and Swallowing

As bulbar function deteriorates, dysphagia creates aspiration risk and inadequate caloric intake. Careful speech-language pathology assessment guides dietary texture modification. When oral feeding becomes unsafe or insufficient, gastrostomy tube (PEG) placement provides nutritional support and reduces aspiration pneumonia risk. Timing this discussion with families requires sensitive advance care planning conversations.

Psychiatric Manifestations in Adult MLD

The psychiatric features of adult-onset MLD — psychosis, depression, behavioral disturbance — require careful pharmacological management. Antipsychotics may help psychotic symptoms but must be used cautiously, as some agents (particularly first-generation antipsychotics) can worsen extrapyramidal symptoms in patients already affected by basal ganglia involvement. Second-generation antipsychotics with lower extrapyramidal risk profiles are generally preferred. Mood stabilizers and antidepressants address affective symptoms. Cognitive-behavioral therapy and psychosocial support for both patient and family are valuable throughout.

Respiratory Support

Advanced disease eventually compromises respiratory muscle function. Non-invasive positive-pressure ventilation (BiPAP/CPAP) can support breathing during sleep and with acute respiratory compromise. Advance care planning — including discussions of ventilator use, tracheostomy, and goals of care — should be initiated early and revisited regularly, before crisis points arise.

Genetic Counseling and Family Planning

MLD carries a 25% recurrence risk per pregnancy in carrier couples. Prenatal diagnosis by measuring ARSA enzyme activity in chorionic villus sampling (CVS) or amniocytes, combined with mutation testing, is available. Preimplantation genetic testing (PGT) allows carrier couples to identify unaffected embryos before transfer during in vitro fertilization. Cascade testing of siblings and extended family members — particularly given the availability of pre-symptomatic treatment — is a high-priority genetic counseling goal.

Back to Table of Contents

Newborn Screening and Future Directions

The approval of gene therapy has fundamentally changed the stakes of early diagnosis in MLD. A disease that previously had no treatment now has a curative-intent intervention — but only for patients identified before significant neurological damage accumulates. This makes newborn screening both scientifically justified and urgently needed.

Newborn Screening Challenges and Pilots

The primary NBS strategy measures ARSA enzyme activity on dried blood spots (DBS) using tandem mass spectrometry. The major challenge remains the pseudodeficiency problem: benign ARSA variants lower enzyme activity on standard assays in approximately 1% of newborns, generating false-positive screens at an unacceptable rate if used alone. A validated two-tier approach using sulfatide biomarker measurement on the same DBS as a reflex confirmatory test is being developed and piloted in multiple countries including Germany, Italy, and the Netherlands. True MLD produces dramatically elevated sulfatides; pseudodeficiency does not.

Pilot NBS programs have successfully identified pre-symptomatic late infantile infants who were then treated with gene therapy — demonstrating proof-of-principle for population-based screening. No US nationwide NBS mandate for MLD exists as of 2026, but advocacy by patient organizations (MLD Foundation, Hunter's Hope) is ongoing.

Second-Generation Gene Therapies

Research into improved gene therapy vectors continues. Second-generation lentiviral vectors with higher transduction efficiency may reduce the manufacturing time and number of cells required. AAV-mediated direct CNS delivery (intracranial or intrathecal administration) is being studied in preclinical models and early trials, with the goal of bypassing the need for myeloablative conditioning and potentially treating symptomatic patients where current gene therapy cannot.

Intrathecal Enzyme Replacement Therapy

Intravenous enzyme replacement therapy (ERT) with recombinant ARSA cannot cross the blood-brain barrier in sufficient quantities to treat CNS disease — a fundamental limitation that distinguishes MLD from lysosomal storage disorders confined to peripheral tissues. Intrathecal delivery of recombinant ARSA (HGT-1111, formerly developed by Shire, now Takeda) bypasses this barrier by injecting enzyme directly into the cerebrospinal fluid. Phase I/II trials demonstrated reduction of CSF sulfatide levels and suggested some MRI stabilization. Larger efficacy studies are ongoing. IT-ERT could potentially treat symptomatic patients who are beyond gene therapy eligibility — filling a major current gap in the treatment landscape.

Small Molecule and Substrate Reduction Approaches

Pharmacological chaperones — small molecules that stabilize misfolded ARSA protein produced by missense mutations — could restore residual enzyme activity in patients with certain genotypes. This approach has been successfully translated in Gaucher disease (miglustat, eliglustat) and Fabry disease (migalastat), providing a roadmap for MLD. Substrate reduction therapy — inhibiting enzymes required for sulfatide synthesis upstream of ARSA — is another strategy under preclinical investigation. These small-molecule approaches are particularly attractive for adult-onset patients where the risk-benefit profile of gene therapy may be less compelling.

Patient Registries and Natural History Data

Rare disease research depends critically on robust natural history data. The European MLD Registry and international collaborators continue to collect longitudinal data on untreated patients, enabling rigorous comparison with treated cohorts. As gene therapy rollout expands, real-world outcome data will be essential for understanding long-term durability, late adverse effects, and which patients benefit most from each intervention. The MLD Foundation provides patient advocacy, registry participation encouragement, NBS lobbying, and family support services.

Back to Table of Contents

Key Research Papers

  1. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. PMID: 23845948 — Landmark proof-of-concept study demonstrating that ex vivo lentiviral gene therapy in HSPCs prevents or arrests neurological disease in MLD, with treated patients showing near-normal development compared to severely affected untreated controls.
  2. Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy — an update. Neuropediatrics. 2010;41(1):1-6. PMID: 20571983 — Comprehensive review of MLD pathophysiology, clinical forms, diagnosis, and treatment landscape from leading MLD researchers.
  3. Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016;388(10043):476-487. PMID: 27289174 — Phase I/II data showing stabilization and near-normal development in pre-symptomatic late infantile patients treated with gene therapy, with untreated siblings serving as natural history comparators.
  4. Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2022;399(10322):372-383. PMID: 35065008 — Extended long-term follow-up of the gene therapy cohort, confirming sustained clinical benefit and supporting the regulatory dossier for Libmeldy approval.
  5. Kehrer C, Groeschel S, Kustermann-Kuhn B, et al. Disease course and treatment effects of hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy. Orphanet J Rare Dis. 2014;9:161. PMID: 25366935 — Analysis of HSCT outcomes in juvenile MLD, characterizing which patients benefit most and informing selection criteria for the pre-gene-therapy era and ongoing HSCT use.
  6. Krägeloh-Mann I, Groeschel S, Kehrer C, et al. A multicenter study into the natural history of metachromatic leukodystrophy in Europe. Neurology. 2013;81(10):945-952. PMID: 23925756 — Essential natural history dataset from the European MLD Registry providing the baseline for comparison with gene therapy outcomes.
  7. Cesani M, Lorioli L, Grossi S, et al. Mutation update of ARSA and PSAP genes causing metachromatic leukodystrophy. Hum Mutat. 2016;37(1):16-27. PMID: 26358691 — Comprehensive catalog of disease-causing variants in ARSA and PSAP, with genotype-phenotype correlations and guidance for molecular diagnosis.
  8. Dvorakova L, Hruba E, Hrebicek M, et al. Comprehensive pseudodeficiency ARSA genotyping: different frequency in MLD and pseudodeficiency. Eur J Hum Genet. 2006;14(10):1065-1073. PMID: 16788716 — Characterization of ARSA pseudodeficiency alleles and their frequency, providing the molecular basis for distinguishing true MLD from the clinically irrelevant pseudodeficiency state.
  9. Martin A, Gavrilova RH, Davis MD, et al. Intrathecal enzyme replacement therapy (HGT-1111) in late-infantile and late-onset metachromatic leukodystrophy. J Inherit Metab Dis. 2018;41(6):1209-1220. PMID: 30194510 — Phase I/II data on intrathecal recombinant ARSA delivery showing CSF sulfatide reduction, advancing IT-ERT as a potential treatment for symptomatic MLD patients beyond gene therapy eligibility.
  10. Ries M, Gupta S, Moore DF, et al. Systemic arylsulfatase A gene therapy rescues metachromatic leukodystrophy mice. Ann Neurol. 2006;60(1):103-113. PMID: 16802295 — Preclinical murine gene therapy study demonstrating rescue of the MLD phenotype, providing foundational evidence for the clinical development of lentiviral gene therapy.
  11. von Figura K, Gieselmann V, Jaeken J. Metachromatic leukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. (Textbook chapter — no PMID; foundational reference for MLD biochemistry and clinical classification.)
  12. Patil SA, Maegawa GH. Developing therapeutic approaches for metachromatic leukodystrophy. Degener Neurol Neuromuscul Dis. 2013;3:49-56. PubMed search: MLD therapeutic approaches — Review of the developing treatment landscape including gene therapy, HSCT, ERT, and small molecule strategies for MLD.

Back to Table of Contents

Connections

Back to Table of Contents